Literature DB >> 4726153

Development of extrapyramidal symptoms in hypertensive patients treated with diazoxide.

D Neary, H Thurston, J E Pohl.   

Abstract

Extrapyramidal symptoms developed a variable time after the start of treatment with oral diazoxide in 15% of a series of 100 severely hypertensive patients. Six illustrative cases are described. Treatment with diazoxide could be continued in four of these. The symptoms are usually controllable either by dosage adjustment or by the use of diazepam or procyclidine. There was no evidence of irreversibility of the extrapyramidal syndromes observed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4726153      PMCID: PMC1586584          DOI: 10.1136/bmj.3.5878.474

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  DIAZOXIDE HYPERGLYCAEMIA AND ITS CONTINUED RELIEF BY TOLBUTAMIDE.

Authors:  F WOLFF
Journal:  Lancet       Date:  1964-02-08       Impact factor: 79.321

2.  [Actions of diazoxide on the cardiovascular system, on the metabolism of the myocardium and on sympathetic discharges].

Authors:  H Schmitt; M Laubie
Journal:  Arch Int Pharmacodyn Ther       Date:  1968-02

3.  Sodium conservation in chronic renal failure: studies using oral diazoxide.

Authors:  J D Swales; H Thurston; J E Pohl
Journal:  Clin Sci       Date:  1972-12       Impact factor: 6.124

4.  The dntidiuretic action of diazoxide.

Authors:  J E Pohl; H Thurston; J D Swales
Journal:  Clin Sci       Date:  1972-02       Impact factor: 6.124

5.  Some effects of the hypotensive drug diazoxide on the cardiovascular system.

Authors:  W G Nayler; I McInnes; J B Swann; D Race; V Carson; T E Lowe
Journal:  Am Heart J       Date:  1968-02       Impact factor: 4.749

6.  Protein binding and vascular activity of diazoxide.

Authors:  E M Sellers; J Koch-Weser
Journal:  N Engl J Med       Date:  1969-11-20       Impact factor: 91.245

7.  The long term effect of repeated acute reductions of arterial pressure with diazoxide in patients with severe hypertension.

Authors:  F A Finnerty; N Kakaviatos; M Davidov
Journal:  Ann N Y Acad Sci       Date:  1968-04-11       Impact factor: 5.691

8.  Successful use of oral diazoxide in the treatment of severe toxaemia of pregnancy.

Authors:  J E Pohl; H Thurston; D Davis; M Y Morgan
Journal:  Br Med J       Date:  1972-06-03

9.  Use of diazoxide in hypertension with renal failure.

Authors:  J E Pohl; H Thurston
Journal:  Br Med J       Date:  1971-10-16
  9 in total
  6 in total

1.  Diazoxide in treatment of hypertension.

Authors:  K T Farn
Journal:  Br Med J       Date:  1976-09-04

2.  Complications of diazoxide in the treatment of nesidioblastosis.

Authors:  M E McGraw; D A Price
Journal:  Arch Dis Child       Date:  1985-01       Impact factor: 3.791

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 4.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 5.  Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies.

Authors:  Soumiya Pal; Jenat Rahman; Shengyu Mu; Nancy J Rusch; Amanda J Stolarz
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

6.  KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema.

Authors:  Brittney R Garner; Amanda J Stolarz; Daniel Stuckey; Mustafa Sarimollaoglu; Yunmeng Liu; Philip T Palade; Nancy J Rusch; Shengyu Mu
Journal:  J Pharmacol Exp Ther       Date:  2020-10-25       Impact factor: 4.030

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.